31 October 2020 in Annals of Rehabilitation Medicine
Objective To compare the accuracy of ultrasound-guided and non-guided botulinum toxin injections into the neck muscles involved in cervical dystonia.Methods Two physicians examined six muscles (sternocleidomastoid, upper trapezius, levator scapulae, splenius capitis, scalenus anterior, and scalenus medius) from six fresh cadavers. Each physician injected ultrasound-guided and non-guided injections to each side of the cadaver’s neck muscles, respectively. Each physician then dissected the other physician’s injected muscle to identify the injection results. For each injection technique, different colored dyes were used. Dissection was performed to identify the results of the injections. The muscles were divided into two groups based on the difficulty of access: sternocleidomastoid and upper trapezius muscles (group A) and the levator scapulae, splenius capitis, scalenus anterior, and scalenus medius muscles (group B).Results The ultrasound-guided and non-guided injection accuracies of the group B muscles were 95.8% and 54.2%, respectively (p<0.001), while the ultrasound-guided and non-guided injection accuracies of the group A muscles were 100% and 79.2%, respectively (p<0.05).Conclusion Ultrasound-guided botulinum toxin injections into inaccessible neck muscles provide a higher degree of accuracy than non-guided injections. It may also be desirable to consider performing ultrasound-guided injections into accessible neck muscles.
31 October 2018 in Annals of Rehabilitation Medicine
Spinal accessory nerve (SAN) injury mostly occurs during surgical procedures. SAN injury caused by manipulation therapy has been rarely reported. We present a rare case of SAN injury associated with manipulation therapy showing scapular winging and droopy shoulder. A 42-year-old woman visited our outpatient clinic complaining of pain and limited active range of motion (ROM) in right shoulder and scapular winging after manipulation therapy. Needle electromyography and nerve conduction study suggested SAN injury. Physical therapy (PT) three times a week for 2 weeks were prescribed. After a total of 6 sessions of PT and modality, the patient reported that the pain was gradually relieved during shoulder flexion and abduction with improved active ROM of shoulder. Over the course of 2 months follow-up, the patient reported almost recovered shoulder ROM and strength as before. She did not complain of shoulder pain any more.
1 January 2018 in Annals of Rehabilitation Medicine
Kim KT, et al. Ann Rehabil Med. 2018 Apr;42(2):321-328. https://doi.org/10.5535/arm.2018.42.2.321
1 January 2018 in Brain & Neurorehabilitation
Yoon JR, et al. Brain Neurorehabil. 2018 Jan;11:e2. https://doi.org/10.12786/bn.2018.11.e2
30 September 2025 in Precision and Future Medicine
Purpose: Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) are major gynecological malignancies. Precision oncology seeks to tailor treatments by targeting tumor-specific molecular profiles. Solute carriers (SLCs), a superfamily of over 400 transport proteins in 65 families, regulate molecular transport and represent potential therapeutic targets.Methods: Transcriptomic and proteomic datasets from The Cancer Genome Atlas and Human Protein Atlas were analyzed to evaluate the role of SLC transporters in CESC.Results: Comparative profiling revealed significant upregulation of SLC64A1, SLC7A1, SLC25A24, and SLC11A2 in tumor tissues versus normal controls. Elevated expression of these SLC genes correlated with reduced overall and disease-specific survival. Gene Set Enrichment Analysis showed enrichment of oncogenic pathways associated with SLC overexpression, including epithelial-mesenchymal transition, hypoxia, angiogenesis, ATP-binding cassette transporter activity, and transforming growth factor-beta, Notch, and Hedgehog signaling. These findings suggest that SLC transporters facilitate tumor progression and metastasis.Conclusion: SLC transporters may serve as predictive biomarkers and therapeutic targets. Their inhibition could disrupt metabolic and nutrient pathways essential for CESC progression, offering novel opportunities to improve outcomes.